Variability in time to response in severe asthma biologics: a SHARP survey

<bold>Background:</bold> Clinicians and patient have noticed variability in time to response to biologics. <bold>Aims:</bold> To explore this variability using a patient conceived survey <bold>Methods:</bold> In collaboration with the Severe Heterogeneous Asthma Research Collaboration Patient-centered (SHARP) registry, we developed and collected survey data from severe asthma patients who had started a biologic >6 months but <18 months ago. <bold>Results:</bold> A total of 269 patients participated, and 204 fully completed the survey. Majority of patients were female (58%) with a mean age of 56 years (±14). Patients were recruited by Croatia (15%), Belgium (14%), Serbia (12%), Iceland (11%), Slovenia (10%), UK (10%), Poland (9%), Hungary (5%), Greece (5%), Sweden (5%) and Czech Republic (4%). Patients reported using Benralizumab (29%), Dupilumab (24%), Mepolizumab (17%), Tezepelumab (17%), Omalizumab (11%) and Reslizumab (2%). The majority of participants (57%) reported a change within the first two months. Among these participants, 74% of them noticed changes at the end of the first month and between 1 and 2 months, while 18% observed changes at the end of the first week and for the last 8% of them the day after the injection. Conversely, 4% of participants did not notice any changes. The majority of participants (81%) reached peak benefit within the first three months, with 31% of them within the first month and 7% and 5% of them within the first week and the first two days respectively. For 19% of all participants, peak benefit was achieved after three months. 40% of participants declared the biologic was life changing. <bold>Conclusion:</bold> This study showed a variability in the time to observe any changes as well as in the time get peak benefit of biologics.